AIP Mediates the Effects of Somatostatin Analogues in Acromegaly - Evidence from Clinical and Experimental Studies.

AIP Mediates the Effects of Somatostatin Analogues in Acromegaly - Evidence from Clinical and Experimental Studies.

Dades bibliogràfiques
Autors principals:	Chahal, H, Alband, N, Ansorge, O, Karavitaki, N, Carlsen, E, Wass, J, Grossman, AB, Korbonits, M
Format:	Conference item
Publicat:	2010

Ítems similars

Somatostatin Analogue Treatment Increases AIP Protein Expression in Somatotroph Tumours from Patients with Acromegaly and in GH3 Cells in vitro.
per: Chahal, H, et al.
Publicat: (2011)

Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.
per: Chahal, H, et al.
Publicat: (2012)

Acromegaly: Treatment with somatostatin analogs
per: Karavitaki, N, et al.
Publicat: (2005)

Pituitary imaging using a labelled somatostatin analogue in acromegaly.
per: Ur, E, et al.
Publicat: (1992)

The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
per: Karavitaki, N, et al.
Publicat: (2005)

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
per: Grozinsky-Glasberg, S, et al.
Publicat: (2008)

CURRENT VIEWS ON THE TREATMENT OF ACROMEGALY WITH SOMATOSTATIN ANALOGUES
per: I. A. Ilovaiskaya
Publicat: (2017-12-01)

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
per: Jenkins, P, et al.
Publicat: (2000)

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
per: Grozinsky-Glasberg, S, et al.
Publicat: (2008)

Association of Pathology Markers with Somatostatin Analogue Responsiveness in Acromegaly
per: George Kontogeorgos, et al.
Publicat: (2022-01-01)

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
per: Sang Ouk Chin, et al.
Publicat: (2019-03-01)

Effects of Somatostatin Analogues on Glucose Metabolism in Acromegaly: Friend of Foe?
per: Corin Badiu, MD, PhD
Publicat: (2016-01-01)

Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation?
per: Fernandez, A, et al.
Publicat: (2008)

Active postoperative acromegaly: sustained remission after discontinuation of somatostatin analogues
per: Cristina Alvarez-Escola, et al.
Publicat: (2016-11-01)

Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues
per: Cecilia Follin, et al.
Publicat: (2016-08-01)

Antiangiogenic effects of somatostatin analogues.
per: García de la Torre, N, et al.
Publicat: (2002)

Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort.
per: Preda, V, et al.
Publicat: (2014)

Pegvisomant: a new treatment modality for acromegaly.
per: Karavitaki, N, et al.
Publicat: (2004)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
per: Adrian F Daly, et al.
Publicat: (2019-04-01)

The Pathogenic Role of AIP Mutations - The Importance of the Integration of Clinical, Experimental and Modeling Data on Advising Patients and Their Families with Pituitary Adenoma Predisposition.
per: Trivellin, G, et al.
Publicat: (2010)

Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas.
per: Larkin, S, et al.
Publicat: (2013)

Increased population risk of AIP-related acromegaly and gigantism in Ireland.
per: Radian, S, et al.
Publicat: (2016)

Acute octreotide suppression test (100 mu g sc): a valuable tool for predicting the long-term response to the long-acting somatostatin analogs in patients with active acromegaly
per: Karavitaki, N, et al.
Publicat: (2005)

Adherence to somatostatin analog therapy for acromegaly
per: I. A. Ilovayskaya
Publicat: (2021-05-01)

Long-Term Results of Cabergoline Add-on Long-Acting Somatostatin Analogue Therapy in Acromegaly Patients
per: Mehmet Muhittin Yalçın, et al.
Publicat: (2024-10-01)

Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study
per: Ming Shen, et al.
Publicat: (2018-01-01)

Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
per: Lingyun Ma, et al.
Publicat: (2020-08-01)

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
per: Kaltsas, G, et al.
Publicat: (2005)

Erratum to “Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study”
per: Ming Shen, et al.
Publicat: (2019-01-01)

Novel Somatostatin Receptor Ligands Therapies for Acromegaly
per: Rosa Maria Paragliola, et al.
Publicat: (2018-03-01)

The Dose of Somatostatin Analogues during Pre-Surgical Treatment Is a Key Factor to Achieve Surgical Remission in Acromegaly
per: Marta Araujo-Castro, et al.
Publicat: (2021-08-01)

Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
per: Ur, E, et al.
Publicat: (1993)

Evidence for the effectiveness of radiotherapy in the treatment of acromegaly.
per: Wass, J
Publicat: (1997)

AIP, a Protein Mutated in Familial Acromegaly, Plays a Role in the Regulation of Cell Proliferation and Shows Cell-Type Specific Subcellular Localisation
per: Leontiou, C, et al.
Publicat: (2009)

Hypercalcaemia in acromegaly is not always due to men-1
per: Zabuliene, L, et al.
Publicat: (2005)

Rathke's cleft cysts.
per: Trifanescu, R, et al.
Publicat: (2012)

Growth hormone-releasing peptides (GHRP) and their analogues
per: Korbonits, M, et al.
Publicat: (1996)

[Growth hormone-releasing peptides (GHRP) and their analogues]
per: Korbonits, M, et al.
Publicat: (1996)

Epithelial–Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly
per: Joan Gil, et al.
Publicat: (2021-03-01)

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.
per: Hubina, E, et al.
Publicat: (2006)